The acquisition will increase Hoboken-based Genesis’ headcount from 145 to 215 across four international locations.
Genesis Research has an established footprint in the U.S. and U.K. It optimizes drug development and evidences the clinical and commercial value of products via expert analysis, synthesis, communication and utilization of real-world data.
By adding MAT, Genesis Research’s offering will be enhanced and be able to help life sciences companies to generate insights and assess commercial viability faster and more comprehensively than ever before.
MAT’s two technology platforms have revolutionized the way companies conduct payer research and evaluate the market access viability of their products.
“The life sciences sector has repeatedly seen the challenges associated with demonstrating the value of new products,” Frank Corvino, CEO of Genesis Research said. “The combination of Genesis Research and MAT creates a novel and unparalleled approach to generating payer insights and evidence. This will enable life sciences companies to both identify and answer the right questions faster than ever before, without sacrificing scientific rigor or transparency.”